The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2015 | Overview of a Phase I study of ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Martin Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase I study of ONO/GS-4059, a selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed and refractory mature B-cell malignancies. Prof. Dyer presents the data showing the reduced toxicity of ONO/GS-4059 in comparison with the 1st generation BTK inhibitor ibrutinib.
